Coronary Artery Disease – Pipeline Review, 2019

Coronary artery disease is characterized by a condition in which the coronary arteries of the heart is clogged by the buildup of fatty acids and cholesterol. This plaque formation is usually called atherosclerosis. Some of the major symptoms of coronary artery disease include chest pain, stable angina, ischemia among others. The major factors causing coronary artery disease comprise of diabetes, high cholesterol, high blood pressure, excessive consumption of alcohol, and smoking among others.

Current treatment of coronary artery disease includes angioplasty, coronary artery bypass grafting, stent implantation, lifestyle modifications, and drugs. Therapeutic drugs, for instance, beta blockers, antiplatelet drugs, statins are prescribed for the treatment of coronary artery disease. Making changes to the diet to lower blood cholesterol level and exercising is one of the primary factors to control heart disease.

Research organization and pharmaceutical companies are working in collaboration to discover effective treatment methods for coronary artery disease. The treatment options studies include devices as well as therapeutic drugs. For instance, AZD5718 is a drug being developed by AstraZeneca is currently in Phase 2 clinical trial.

Currently, around 45% of the clinical trials are in Phase 2 stage. Approximately 70% of the clinical trials are being conducted by government institutes and research organizations.

Report Description

The report on ‘Coronary Artery Disease – Pipeline Review, 2019’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for coronary artery disease. The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for Coronary Artery Disease.

The report on ‘Coronary Artery Disease – Pipeline Review, 2019’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players.

Report Scope

• Thorough assessment of the pipeline products by areas such as development stage; route of administration; drug class; indication; sponsor; molecule type and drug target


• Comprehensive profiles of the pipeline products with details such as company overview; product description; R&D status; development activities; mechanism of action; molecule type; development stage; indications; funding and route of administration


• Overview of dormant and discontinued pipeline products


• Key insights in relation to the epidemiology of conditions being treated by the pipeline products and overview of the addressable or current market for the pipeline products


• Overview of the latest developments; news articles, press releases and relevant conferences

Report Methodology

• All pipeline reports are built through the analysis of data primarily collected through credible desk research sources. Secondary research is supplemented by interviews conducted with key opinion leaders.


• Desk research sources includes global and regional clinical trials databases; annual reports, websites, press releases & investor presentations of companies; white papers; news articles; reports published by industry associations; articles/reports published on databases such as NCBI, ResearchGate; internal databases

Reasons to Buy this Report

• Develop effective growth strategies based on comprehensive overview of the R&D activity and pipeline products for coronary artery disease


• Identify emerging players or competition in the market based on pipeline products and develop strategies to counter the emergence of these players


• Identify the focus of leading players in relation to R&D for coronary artery disease


• Identify potential companies from a partnership or acquisition point of view based on current synergy in R&D activities or strategies to diversify R&D focus to drive growth in business


• Analyse the reasons behind dormant and discontinued products to make changes in the R&D focus if necessary